35 results on '"Darrieux, Michelle"'
Search Results
2. Current Stage in the Development of Klebsiella pneumoniae Vaccines
- Author
-
Assoni, Lucas, Girardello, Raquel, Converso, Thiago Rojas, and Darrieux, Michelle
- Published
- 2021
- Full Text
- View/download PDF
3. Recent advances in the therapeutic potential of cathelicidins.
- Author
-
Souza Guerra, Maria Eduarda, Vieira, Brenda, Carvalho Thiers Calazans, Ana Paula, Destro Karina Melo, Giulia Vicente, Rodrigues, Emilly, Tedeschi Waz, Natalha, Girardello, Raquel, Darrieux, Michelle, and Rojas Converso, Thiago
- Subjects
CATHELICIDINS ,ANTIMICROBIAL peptides ,SYNTHETIC biology ,BACTERIAL diseases ,AUTOIMMUNE diseases ,VIRUS diseases - Abstract
The alarming increase in antimicrobial resistance in the last decades has prompted the search for alternatives to control infectious diseases. Antimicrobial peptides (AMPs) represent a heterogeneous class of molecules with ample antibacterial, antiviral, and antifungal effects. They can be found in many organisms, including all classes of vertebrates, providing a valuable source of new antimicrobial agents. The unique properties of AMPs make it harder for microbes develop resistance, while their immunomodulatory properties and target diversity reinforce their translational use in multiple diseases, from autoimmune disorders to different types of cancer. The latest years have witnessed a vast number of studies evaluating the use of AMPs in therapy, with many progressing to clinical trials. The present review explores the recent developments in the medicinal properties of cathelicidins, a vast family of AMPs with potent antimicrobial and immunomodulatory effects. Cathelicidins from several organisms have been tested in disease models of viral and bacterial infections, inflammatory diseases, and tumors, with encouraging results. Combining nanomaterials with active, natural antimicrobial peptides, including LL-37 and synthetic analogs like ceragenins, leads to the creation of innovative nanoagents with significant clinical promise. However, there are still important limitations, such as the toxicity of many cathelicidins to healthy host cells and low stability in vivo. The recent advances in nanomaterials and synthetic biology may help overcome the current limitations, enabling the use of cathelicidins in future therapeutics. Furthermore, a better understanding of the mechanisms of cathelicidin action in vivo and their synergy with other host molecules will contribute to the development of safer, highly effective therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Animal models of Klebsiella pneumoniae mucosal infections.
- Author
-
Assoni, Lucas, Melo Couto, Ana Julia, Vieira, Brenda, Milani, Bárbara, Lima, Alice Souza, Converso, Thiago Rojas, and Darrieux, Michelle
- Subjects
KLEBSIELLA pneumoniae ,BRACHYDANIO ,ANIMAL models in research ,MUCOUS membranes ,GREATER wax moth ,DROSOPHILA melanogaster - Abstract
Klebsiella pneumoniae is among the most relevant pathogens worldwide, causing high morbidity and mortality, which is worsened by the increasing rates of antibiotic resistance. It is a constituent of the host microbiota of different mucosa, that can invade and cause infections in many different sites. The development of new treatments and prophylaxis against this pathogen rely on animal models to identify potential targets and evaluate the efficacy and possible side effects of therapeutic agents or vaccines. However, the validity of data generated is highly dependable on choosing models that can adequately reproduce the hallmarks of human diseases. The present review summarizes the current knowledge on animal models used to investigate K. pneumoniae infections, with a focus on mucosal sites. The advantages and limitations of each model are discussed and compared; the applications, extrapolations to human subjects and future modifications that can improve the current techniques are also presented. While mice are the most widely used species in K. pneumoniae animal studies, they present limitations such as the natural resistance to the pathogen and difficulties in reproducing the main steps of human mucosal infections. Other models, such as Drosophila melanogaster (fruit fly), Caenorhabditis elegans, Galleria mellonella and Danio rerio (zebrafish), contribute to understanding specific aspects of the infection process, such as bacterial lethality and colonization and innate immune system response, however, they but do not present the immunological complexity of mammals. In conclusion, the choice of the animal model of K. pneumoniae infection will depend mainly on the questions being addressed by the study, while a better understanding of the interplay between bacterial virulence factors and animal host responses will provide a deeper comprehension of the disease process and aid in the development of effective preventive/therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Robust Immune Response and Protection against Lethal Pneumococcal Challenge with a Recombinant BCG-PspA-PdT Prime/Boost Scheme Administered to Neonatal Mice.
- Author
-
Trentini, Monalisa Martins, Rodriguez, Dunia, Kanno, Alex Issamu, Goulart, Cibelly, Darrieux, Michelle, and de Cerqueira Leite, Luciana Cezar
- Subjects
IMMUNE response ,B cells ,T cells ,PNEUMOCOCCAL vaccines ,STREPTOCOCCAL diseases - Abstract
Pneumococcal diseases are an important public health problem, with high mortality rates in young children. Although conjugated pneumococcal vaccines offer high protection against invasive pneumococcal diseases, this is restricted to vaccine serotypes, leading to serotype replacement. Furthermore, the current vaccines do not protect neonates. Therefore, several protein-based pneumococcal vaccines have been studied over the last few decades. Our group established a recombinant BCG expressing rPspA-PdT as a prime/rPspA-PdT boost strategy, which protected adult mice against lethal intranasal pneumococcal challenge. Here, we immunized groups of neonate C57/Bl6 mice (6–10) (at 5 days) with rBCG PspA-PdT and a boost with rPspA-PdT (at 12 days). Controls were saline or each antigen alone. The prime/boost strategy promoted an IgG1 to IgG2c isotype shift compared to protein alone. Furthermore, there was an increase in specific memory cells (T and B lymphocytes) and higher cytokine production (IFN-γ, IL-17, TNF-α, IL-10, and IL-6). Immunization with rBCG PspA-PdT/rPspA-PdT showed 100% protection against pulmonary challenge with the WU2 pneumococcal strain; two doses of rPspA-PdT showed non-significant protection in the neonates. These results demonstrate that a prime/boost strategy using rBCG PspA-PdT/rPspA-PdT is effective in protecting neonates against lethal pneumococcal infection via the induction of strong antibody and cytokine responses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Fusion of PspA to detoxified pneumolysin enhances pneumococcal vaccine coverage.
- Author
-
Milani, Barbara, dos Santos, Tanila Wood, Guerra, Maria Eduarda Souza, Oliveira, Sheila, Goulart, Cibelly, André, Greiciely O., Leite, Luciana C. C., Converso, Thiago R, and Darrieux, Michelle
- Subjects
VACCINATION coverage ,PNEUMOCOCCAL vaccines ,COMPLEMENT (Immunology) ,COMPLEMENT receptors - Abstract
Despite the implementation of conjugate vaccines in several countries, S. pneumoniae continues to pose a great burden worldwide, causing around 1 million annual deaths. Pneumococcal proteins have long been investigated as serotype-independent vaccines against this pathogen, with promising results. However, it is a consensus that one antigen alone will not be sufficient to provide long-term protection with wide coverage. Amongst the most well studied pneumococcal proteins are PspA and pneumolysin (Ply), two major virulence factors required by the bacterium for successful invasion of host tissues. PspA is highly immunogenic and protective, but it is structurally variable; pneumolysin is conserved among different pneumococci, but it is toxic to the host. To overcome these limitations, N-terminal PspA fragments have been genetically fused to non-toxic pneumolysin derivatives (PlD) to create PspA_PlD chimeras. Mouse immunization with these fusions confers protection against pneumococcal strains expressing heterologous PspAs, which correlates with antibody-induced complement C3 deposition on the surface of multiple pneumococcal strains. Analysis of mutant strains lacking PspA or Pneumolysin shows that both proteins contribute to the antibody-mediated enhancement in complement deposition induced by the fusion. These results expand previous data evaluating PspA_PlD and demonstrate that the fusion combines the protective traits of both proteins, inducing antibodies that efficiently promote complement deposition on multiple strains and cross-protection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine
- Author
-
Campos, Ivana B., Herd, Muriel, Moffitt, Kristin L., Lu, Ying-Jie, Darrieux, Michelle, Malley, Richard, Leite, Luciana C.C., and Gonçalves, Viviane M.
- Published
- 2017
- Full Text
- View/download PDF
8. Selection and validation of reference genes for gene expression studies in Klebsiella pneumoniae using Reverse Transcription Quantitative real-time PCR
- Author
-
Gomes, Ana Érika Inácio, Stuchi, Leonardo Prado, Siqueira, Nathália Maria Gonçalves, Henrique, João Batista, Vicentini, Renato, Ribeiro, Marcelo Lima, Darrieux, Michelle, and Ferraz, Lúcio Fábio Caldas
- Published
- 2018
- Full Text
- View/download PDF
9. A fusion protein comprising pneumococcal surface protein A and a pneumolysin derivate confers protection in a murine model of pneumococcal pneumonia.
- Author
-
dos Santos, Tanila Wood, Gonçalves, Pedro Almeida, Rodriguez, Dunia, Pereira, José Aires, Martinez, Carlos Augusto Real, Leite, Luciana C. C., Ferraz, Lucio F. C., Converso, Thiago Rojas, and Darrieux, Michelle
- Subjects
PNEUMOCOCCAL pneumonia ,STREPTOCOCCAL diseases ,NEUROENDOCRINE cells ,PNEUMOCOCCAL vaccines ,VACCINE effectiveness ,PNEUMONIA - Abstract
PspA and pneumolysin are two important vaccine candidates, able to elicit protection in different models of pneumococcal infection. The high immunogenic potential of PspA, combined with a possible adjuvant effect of pneumolysin derivatives (due to their ability to interact with TLR-4) could greatly improve the immunogenicity and coverage of a protein-based pneumococcal vaccine. A chimeric protein including the N-terminal region of PspA in fusion with the pneumolysin derivative, PlD1, has been shown to induce high antibody levels against each protein, and protect mice against invasive challenge. The aim of the present study was to investigate the cellular response induced by such vaccine, and to evaluate protection in a murine model of lobar pneumococcal pneumonia. Pneumococcal pneumonia was induced in BALB/c mice by nasal instillation of a high dose of a serotype 14 strain with low virulence. Airway inflammation was confirmed by total and differential cell counts in BAL and by histological analysis of the lungs, and bacterial loads were measured 7 days after challenge. Cytokine levels were determined in the bronchoalveolar fluid (BALF) of mice immunized with rPspA-PlD1 fusion after challenge, by flow cytometry and ELISA. After challenge, the mice developed lung inflammation with no invasion of other sites, as demonstrated by histological analysis. We detected significant production of TNF-α and IL-6 in the BALF, which correlated with protection against pneumonia in the group immunized with rPspA-PlD1. In conclusion, we found that the rPspA-PlD1fusion is protective against pneumococcal pneumonia in mice, and protection is correlated with an early and controlled local inflammatory response. These results are in agreement with previous data demonstrating the efficacy of the fusion protein against pneumococcal sepsis and reinforce the potential of the rPspA-PlD1 protein chimera as a promising vaccine strategy to prevent pneumococcal disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Immune response induced in mice by a hybrid rPotD-PdT pneumococcal protein.
- Author
-
Rojas Converso, Thiago, Goulart, Cibelly, Rodriguez, Dunia, Guerra, Maria Eduarda Souza, Darrieux, Michelle, and Leite, Luciana C. C.
- Subjects
IMMUNE response ,CARRIER proteins ,PNEUMOCOCCAL meningitis ,STREPTOCOCCUS pneumoniae ,PROTEINS ,PROTEIN transport ,MENINGITIS ,FC receptors - Abstract
Streptococcus pneumoniae is a human pathogen that colonizes the naso and/or oropharynx and can cause otitis, pneumonia, bacteremia and meningitis. To broaden the protection against pneumococcus, several pneumococcal proteins have been investigated as vaccine candidates. In this study we analyzed the immunological response induced by mouse subcutaneous immunization with a fusion of the Polyamine transport protein D (PotD) and a pneumolysin derivative (PdT), resulting in a hybrid rPotD-PdT protein. Immunization of mice with rPotD-PdT induced increased production of nitric oxide, indicating a higher innate immune response. In agreement, immunization of mice with the hybrid protein was more immunogenic than the individual proteins or their combination, eliciting higher antibody levels. The anti-rPotD-PdT IgG displayed increased binding onto the pneumococcal surface. Furthermore, the anti-rPotD-PdT antisera promoted superior opsonophagocytosis as compared with the other tested formulations. However, despite that the encouraging results in vitro, immunization with the hybrid was not sufficient to induce protection against sepsis with a highly virulent pneumococcal strain. taken together, the results suggest that hybrid proteins are an interesting strategy, able to promote improved immune responses, but the inclusion of other antigens may be necessary to promote protection against invasive infections caused by this bacterium. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Influence of the Polysaccharide Capsule on the Bactericidal Activity of Indolicidin on S treptococcus pneumoniae.
- Author
-
Waz, Natalha T., Oliveira, Sheila, Girardello, Raquel, Lincopan, Nilton, Barazzone, Giovana, Parisotto, Thais, Hakansson, Anders P., Converso, Thiago Rojas, and Darrieux, Michelle
- Subjects
POLYSACCHARIDES ,STREPTOCOCCUS pneumoniae ,BACTERICIDAL action ,ANTIMICROBIAL peptides ,PNEUMOCOCCAL vaccines ,PEPTIDES ,SEROTYPES ,SURFACE charges - Abstract
Streptococcus pneumoniae is a pathogen responsible for high morbidity and mortality worldwide. The polysaccharide capsule confers protection against phagocytosis and influences many aspects of pneumococcal pathogenesis. The capsular polysaccharides (CPS) are highly immunogenic and exhibit great structural variability, with more than 100 serotypes described so far. Antimicrobial peptides (AMPs) are an important part of the innate defense mechanisms against many pathogens. Indolicidin is a cationic AMP produced by bovine neutrophils, with bactericidal effects against several bacteria. CPS has been shown to interfere with the ability of AMPs to kill pneumococci, but the effects of capsule variability on susceptibility to indolicidin have not been explored. The present work determined the effects of capsule on resistance to indolicidin in vitro. Using a bactericidal plate assay, we observed that different pneumococcal serotypes exhibited variable resistance to indolicidin, which correlated with the capsule net charge. Interestingly, the effect of capsule expression on resistance to indolicidin was dependent on the serotype; bacteria with lower zeta potential were more resistant to indolicidin when capsule was present, while those with less negative surface charge were more resistant in the absence of capsule. The addition of purified CPS partially rescued the bacteria from the bactericidal effects of indolicidin, while the addition of anticapsular antibodies accentuated the peptide's bactericidal action, suggesting a possible new protective mechanism induced by polysaccharide-based pneumococcal vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Klebsiella pneumoniae Biofilms and Their Role in Disease Pathogenesis.
- Author
-
Guerra, Maria Eduarda Souza, Destro, Giulia, Vieira, Brenda, Lima, Alice S., Ferraz, Lucio Fabio Caldas, Hakansson, Anders P., Darrieux, Michelle, and Converso, Thiago Rojas
- Subjects
KLEBSIELLA pneumoniae ,BIOFILMS ,NOSOCOMIAL infections ,EXTRACELLULAR matrix proteins ,GRAM-negative bacteria ,BACTERIAL communities ,BACTERIAL diseases - Abstract
The ability to form biofilms is a crucial virulence trait for several microorganisms, including Klebsiella pneumoniae – a Gram-negative encapsulated bacterium often associated with nosocomial infections. It is estimated that 65-80% of bacterial infections are biofilm related. Biofilms are complex bacterial communities composed of one or more species encased in an extracellular matrix made of proteins, carbohydrates and genetic material derived from the bacteria themselves as well as from the host. Bacteria in the biofilm are shielded from immune responses and antibiotics. The present review discusses the characteristics of K. pneumoniae biofilms, factors affecting biofilm development, and their contribution to infections. We also explore different model systems designed to study biofilm formation in this species. A great number of factors contribute to biofilm establishment and maintenance in K. pneumoniae , which highlights the importance of this mechanism for the bacterial fitness. Some of these molecules could be used in future vaccines against this bacterium. However, there is still a lack of in vivo models to evaluate the contribution of biofilm development to disease pathogenesis. With that in mind, the combination of different methodologies has great potential to provide a more detailed scenario that more accurately reflects the steps and progression of natural infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Protection induced by pneumococcal surface protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide
- Author
-
Csordas, Fátima C.L., Perciani, Cátia T., Darrieux, Michelle, Gonçalves, Viviane M., Cabrera-Crespo, Joaquim, Takagi, Mickie, Sbrogio-Almeida, Maria E., Leite, Luciana C.C., and Tanizaki, Martha M.
- Published
- 2008
- Full Text
- View/download PDF
14. Association between asthma and enamel defects in primary and young permanent teeth – A systematic review.
- Author
-
Rizzardi, Karina F., da Silva Toledo, Elora, Ferraz, Lucio F. C., Darrieux, Michelle, Girardello, Raquel, de Lima Marson, Fernando A., and Parisotto, Thaís M.
- Published
- 2022
- Full Text
- View/download PDF
15. Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades
- Author
-
Darrieux, Michelle, Moreno, Adriana T., Ferreira, Daniela M., Pimenta, Fabiana C., de Andrade, Ana Lúcia S. S., Lopes, Alexandre P. Y., Leite, Luciana C. C., and Miyaji, Eliane N.
- Published
- 2008
- Full Text
- View/download PDF
16. DNA vaccines expressing pneumococcal surface protein A (PspA) elicit protection levels comparable to recombinant protein
- Author
-
Ferreira, Daniela M., Miyaji, Eliane N., Oliveira, Maria Leonor S., Darrieux, Michelle, Arêas, Ana Paula M., Ho, Paulo L., and Leite, Luciana C. C.
- Published
- 2006
- Full Text
- View/download PDF
17. SdiA, a Quorum-Sensing Regulator, Suppresses Fimbriae Expression, Biofilm Formation, and Quorum-Sensing Signaling Molecules Production in Klebsiella pneumoniae.
- Author
-
Pacheco, Thaisy, Gomes, Ana Érika Inácio, Siqueira, Nathália Maria Gonçalves, Assoni, Lucas, Darrieux, Michelle, Venter, Henrietta, and Ferraz, Lúcio Fábio Caldas
- Subjects
KLEBSIELLA pneumoniae ,CELL adhesion ,BIOFILMS ,BACTERIAL adhesins ,GRAM-negative bacteria ,CELL aggregation ,QUORUM sensing - Abstract
Klebsiella pneumoniae is a Gram-negative pathogen that has become a worldwide concern due to the emergence of multidrug-resistant isolates responsible for various invasive infectious diseases. Biofilm formation constitutes a major virulence factor for K. pneumoniae and relies on the expression of fimbrial adhesins and aggregation of bacterial cells on biotic or abiotic surfaces in a coordinated manner. During biofilm aggregation, bacterial cells communicate with each other through inter- or intra-species interactions mediated by signallng molecules, called autoinducers, in a mechanism known as quorum sensing (QS). In most Gram-negative bacteria, intra-species communication typically involves the LuxI/LuxR system: LuxI synthase produces N -acyl homoserine lactones (AHLs) as autoinducers and the LuxR transcription factor is their cognate receptor. However, K. pneumoniae does not produce AHL but encodes SdiA, an orphan LuxR-type receptor that responds to exogenous AHL molecules produced by other bacterial species. While SdiA regulates several cellular processes and the expression of virulence factors in many pathogens, the role of this regulator in K. pneumoniae remains unknown. In this study, we describe the characterization of sdiA mutant strain of K. pneumoniae. The sdiA mutant strain has increased biofilm formation, which correlates with the increased expression of type 1 fimbriae, thus revealing a repressive role of SdiA in fimbriae expression and bacterial cell adherence and aggregation. On the other hand, SdiA acts as a transcriptional activator of cell division machinery assembly in the septum, since cells lacking SdiA regulator exhibited a filamentary shape rather than the typical rod shape. We also show that K. pneumoniae cells lacking SdiA regulator present constant production of QS autoinducers at maximum levels, suggesting a putative role for SdiA in the regulation of AI-2 production. Taken together, our results demonstrate that SdiA regulates cell division and the expression of virulence factors such as fimbriae expression, biofilm formation, and production of QS autoinducers in K. pneumoniae. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Resistance Mechanisms to Antimicrobial Peptides in Gram-Positive Bacteria.
- Author
-
Assoni, Lucas, Milani, Barbara, Carvalho, Marianna Ribeiro, Nepomuceno, Lucas Natanael, Waz, Natalha Tedeschi, Guerra, Maria Eduarda Souza, Converso, Thiago Rojas, and Darrieux, Michelle
- Subjects
ANTIMICROBIAL peptides ,DRUG resistance in microorganisms ,TREATMENT effectiveness ,DRUG resistance in bacteria ,PATHOGENIC bacteria ,GRAM-positive bacteria ,COLISTIN - Abstract
With the alarming increase of infections caused by pathogenic multidrug-resistant bacteria over the last decades, antimicrobial peptides (AMPs) have been investigated as a potential treatment for those infections, directly through their lytic effect or indirectly, due to their ability to modulate the immune system. There are still concerns regarding the use of such molecules in the treatment of infections, such as cell toxicity and host factors that lead to peptide inhibition. To overcome these limitations, different approaches like peptide modification to reduce toxicity and peptide combinations to improve therapeutic efficacy are being tested. Human defense peptides consist of an important part of the innate immune system, against a myriad of potential aggressors, which have in turn developed different ways to overcome the AMPs microbicidal activities. Since the antimicrobial activity of AMPs vary between Gram-positive and Gram-negative species, so do the bacterial resistance arsenal. This review discusses the mechanisms exploited by Gram-positive bacteria to circumvent killing by antimicrobial peptides. Specifically, the most clinically relevant genera, Streptococcus spp. , Staphylococcus spp., Enterococcus spp. and Gram-positive bacilli, have been explored. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Childhood Obesity and Firmicutes/Bacteroidetes Ratio in the Gut Microbiota: A Systematic Review.
- Author
-
Indiani, Cláudia Maria dos Santos Pereira, Rizzardi, Karina Ferreira, Castelo, Paula Midori, Ferraz, Lúcio Fábio Caldas, Darrieux, Michelle, and Parisotto, Thaís Manzano
- Published
- 2018
- Full Text
- View/download PDF
20. Contribution of Streptococcus Mutans Virulence Factors and Saliva Agglutinating Capacity to Caries Susceptibility in Children: A Preliminary Study.
- Author
-
de Camargo, Eloa Ramalho, Canalle, Jonas Bitencourt, Capozzoli, Rodriguo, dos Santos, Tanila Wood, Ballini, Margareth Bulhman, Ferraz, Lucio Fabio Caldas, Parisotto, Thaís Manzano, and Darrieux, Michelle
- Published
- 2018
- Full Text
- View/download PDF
21. Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity.
- Author
-
Andre, Greiciely O., Converso, Thiago R., Politano, Walter R., Ferraz, Lucio F. C., Ribeiro, Marcelo L., Leite, Luciana C. C., and Darrieux, Michelle
- Subjects
STREPTOCOCCUS pneumoniae ,PNEUMOCOCCAL surface protein A ,ANTIGENS - Abstract
The complement system plays a central role in immune defense against Streptococcus pneumoniae. In order to evade complement attack, pneumococci have evolved a number of mechanisms that limit complement mediated opsonization and subsequent phagocytosis. This review focuses on the strategies employed by pneumococci to circumvent complement mediated immunity, both in vitro and in vivo. At last, since many of the proteins involved in interactions with complement components are vaccine candidates in different stages of validation, we explore the use of these antigens alone or in combination, as potential vaccine approaches that aim at elimination or drastic reduction in the ability of this bacterium to evade complement. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
22. Current status and perspectives on protein-based pneumococcal vaccines.
- Author
-
Darrieux, Michelle, Goulart, Cibelly, Briles, David, and Leite, Luciana Cezar de Cerqueira
- Subjects
- *
PNEUMOCOCCAL vaccines , *PROTEINS , *ANTIGENS , *BACTERIAL genomes , *STREPTOCOCCUS pneumoniae - Abstract
Despite the efforts to expand the availability of conjugate vaccines, pneumococcal diseases still pose an enormous burden worldwide. Therefore, several proteins have been investigated as alternative vaccines, alone or in combination with other antigens. With an increasing array of techniques, many of which arose from the publication of the bacterial genome, several proteins have been identified as potential vaccine candidates, and some have even progressed to clinical trials. Also, whole cell vaccines are being studied for the induction of broad ranging protective responses. Here, we briefly summarize the current knowledge on pneumococcal proteins that are being investigated as potential vaccine candidates against pneumococcal infections, and provide an insight on the future generation of protein-based vaccines against Streptococcus pneumoniae. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
23. Characterization of Protective Immune Responses Induced by Pneumococcal Surface Protein A in Fusion with Pneumolysin Derivatives.
- Author
-
Goulart, Cibelly, Silva, Thais Raquel da, Rodriguez, Dunia, Politano, Walter Rodrigo, Leite, Luciana C. C., and Darrieux, Michelle
- Subjects
IMMUNE response ,PNEUMOCOCCAL surface protein A ,STREPTOLYSIN ,PNEUMOCOCCAL vaccines ,PNEUMOCOCCAL meningitis ,SEPSIS ,BIOTECHNOLOGY ,LABORATORY mice - Abstract
Pneumococcal surface protein A (PspA) and Pneumolysin derivatives (Pds) are important vaccine candidates, which can confer protection in different models of pneumococcal infection. Furthermore, the combination of these two proteins was able to increase protection against pneumococcal sepsis in mice. The present study investigated the potential of hybrid proteins generated by genetic fusion of PspA fragments to Pds to increase cross-protection against fatal pneumococcal infection. Pneumolisoids were fused to the N-terminus of clade 1 or clade 2 pspA gene fragments. Mouse immunization with the fusion proteins induced high levels of antibodies against PspA and Pds, able to bind to intact pneumococci expressing a homologous PspA with the same intensity as antibodies to rPspA alone or the co-administered proteins. However, when antibody binding to pneumococci with heterologous PspAs was examined, antisera to the PspA-Pds fusion molecules showed stronger antibody binding and C3 deposition than antisera to co-administered proteins. In agreement with these results, antisera against the hybrid proteins were more effective in promoting the phagocytosis of bacteria bearing heterologous PspAs in vitro, leading to a significant reduction in the number of bacteria when compared to co-administered proteins. The respective antisera were also capable of neutralizing the lytic activity of Pneumolysin on sheep red blood cells. Finally, mice immunized with fusion proteins were protected against fatal challenge with pneumococcal strains expressing heterologous PspAs. Taken together, the results suggest that PspA-Pd fusion proteins comprise a promising vaccine strategy, able to increase the immune response mediated by cross-reactive antibodies and complement deposition to heterologous strains, and to confer protection against fatal challenge. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
24. Complement mediated protection against Streptococcus pneumoniae induced by PspA–PdT immunization
- Author
-
Goulart, Cibelly, Darrieux, Michelle, Rodrigues, Dunia, and Leite, Luciana C.C.
- Published
- 2012
- Full Text
- View/download PDF
25. Antibodies against chimeric pneumococcal proteins enhance complement deposition on Streptococcus pneumoniae with different genetic backgrounds
- Author
-
Darrieux, Michelle, Goulart, Cibelly, Rodrigues, Dunia, and Leite, Luciana C.C.
- Published
- 2012
- Full Text
- View/download PDF
26. Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells
- Author
-
Goulart, Cibelly, Darrieux, Michelle, Rodriguez, Dunia, Pimenta, Fabiana C., Brandileone, Maria Cristina C., de Andrade, Ana Lucia S.S., and Leite, Luciana C.C.
- Subjects
- *
PERITONEUM , *PNEUMOCOCCAL vaccines , *PROTEIN structure , *SEROLOGY , *IMMUNOGLOBULINS , *MACROPHAGES , *IMMUNE response , *LABORATORY rats - Abstract
Abstract: PspA is one of the most well studied pneumococcal proteins and a promising candidate for a future protein-based anti-pneumococcal vaccine. Nevertheless, its structural and serological variability suggests the inclusion of more than one PspA molecule in order to broaden protection. Since different PspAs exhibit variable levels of cross-reactivity, the selection of the protein combination with the highest coverage potential is an essential step for PspA-based vaccine development. This work investigated the level of cross-reactivity within family 1 PspAs, and established a complement based antibody mediated opsonophagocytic assay for measuring the level of cross-protection. Among a panel of ten family 1 PspA molecules, two of them, one belonging to clade 1 and another from clade 2, induced antibodies capable of enhancing complement deposition and mediating the phagocytic killing by mouse peritoneal macrophages of all pneumococci bearing PspA family 1 strains tested, regardless of their serotype. Therefore, we suggest the inclusion of either one in a PspA-based vaccine, as a representative of family 1. Furthermore, our results suggest that opsonophagocytosis by mouse peritoneal cells can be an efficient means of evaluating the induction of protective immune responses in mice across a large number of strains. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
27. Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge
- Author
-
Campos, Ivana B., Darrieux, Michelle, Ferreira, Daniela M., Miyaji, Eliane N., Silva, Débora A., Arêas, Ana Paula M., Aires, Karina A., Leite, Luciana C.C., Ho, Paulo L., and Oliveira, Maria Leonor S.
- Subjects
- *
LACTOBACILLUS , *STREPTOCOCCUS pneumoniae , *VACCINES , *PROTEINS - Abstract
Abstract: Strategies for the development of new vaccines against Streptococcus pneumoniae infections try to overcome problems such as serotype coverage and high costs, present in currently available vaccines. Formulations based on protein candidates that can induce protection in animal models have been pointed as good alternatives. Among them, the Pneumococcal Surface Protein A (PspA) plays an important role during systemic infection at least in part through the inhibition of complement deposition on the pneumococcal surface, a mechanism of evasion from the immune system. Antigen delivery systems based on live recombinant lactic acid bacteria (LAB) represents a promising strategy for mucosal vaccination, since they are generally regarded as safe bacteria able to elicit both systemic and mucosal immune responses. In this work, the N-terminal region of clade 1 PspA was constitutively expressed in Lactobacillus casei and the recombinant bacteria was tested as a mucosal vaccine in mice. Nasal immunization with L. casei-PspA 1 induced anti-PspA antibodies that were able to bind to pneumococcal strains carrying both clade 1 and clade 2 PspAs and to induce complement deposition on the surface of the bacteria. In addition, an increase in survival of immunized mice after a systemic challenge with a virulent pneumococcal strain was observed. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
28. DNA vaccines based on genetically detoxified derivatives of pneumolysin fail to protect mice against challenge with Streptococcus pneumoniae.
- Author
-
Ferreira, Daniela M., Arêas, Ana Paula M., Darrieux, Michelle, Leite, Luciana C. C., and Miyaji, Eliane N.
- Subjects
POLYSACCHARIDES ,VACCINES ,STREPTOCOCCUS pneumoniae ,ANTIGENS ,PROTEINS ,DNA vaccines ,VACCINATION ,RECOMBINANT proteins - Abstract
The 7-valent polysaccharide conjugate vaccine currently administered against Streptococcus pneumoniae has been shown to be highly effective in high risk-groups, but its use in developing countries will probably not be possible due to high costs. The use of conserved protein antigens using the genetic vaccination strategy is an interesting alternative for the development of a cost-effective vaccine. We have analyzed the potential of DNA vaccines expressing genetically detoxified derivatives of pneumolysin (pneumolysoids) against pneumococcal infections, and compared this with immunization using recombinant protein. The purified recombinant pneumolysoid with the highest residual cytolytic activity was able to confer partial protection against a lethal intraperitoneal challenge, with the induction of high antibody levels. Immunization with DNA vaccines expressing pneumolysoids, on the other hand, induced a significantly lower antibody response and no protection was observed. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
29. Protective role of PhtD and its amino and carboxyl fragments against pneumococcal sepsis.
- Author
-
André, Greiciely O., Borges, Mayara T., Assoni, Lucas, Ferraz, Lucio F.C., Sakshi, Piplani, Adamson, Penelope, Gordon, David L., Ogunniyi, Abiodun D., Venter, Henrietta, Converso, Thiago R., and Darrieux, Michelle
- Subjects
- *
PNEUMOCOCCAL vaccines , *RECOMBINANT proteins , *CARRIER proteins , *SEPSIS , *STREPTOCOCCUS pneumoniae - Abstract
• Subcutaneous immunization with PhtD and its C-terminal fragment (PhtD_Cter) protects mice against pneumococcal challenge. • Vaccine induced protection correlated with an increase in C3 deposition on pneumococci and bacterial killing by phagocytes. • Binding between PhtD to factor H was confirmed by western blot and ELISA. • The FH-binding domain in PhtD is located in the N-terminal portion of the protein. The implementation of polysaccharide-based vaccines has massively reduced the incidence of invasive pneumococcal diseases. However, there is great concern regarding serotype replacement and the increase in antibiotic resistant strains expressing non-vaccine capsular types. In addition, conjugate vaccines have high production costs, a limiting factor for their implementation in mass immunization programs in developing countries. These limitations have prompted the development of novel vaccine strategies for prevention of Streptococcus pneumoniae infections. The use of conserved pneumococcal antigens such as recombinant proteins or protein fragments presents an interesting serotype-independent alternative. Pht is a family of surface-exposed proteins which have been evaluated as potential vaccine candidates with encouraging results. The present work investigated the immune responses elicited by subcutaneous immunization of mice with the polyhistidine triad protein D (PhtD) and its amino and carboxyl terminal fragments. The proteins were immunogenic and protective against pneumococcal sepsis in mice. Antibodies raised against PhtD increased complement C3b deposition on the pneumococcal surface, mainly mediated by the alternative pathway. Sera from mice immunized with PhtD and PhtD_Cter promoted an increase in bacterial uptake by mouse phagocytes. The interaction of PhtD with the complement system regulator factor H was investigated in silico and in vitro by ELISA and western blot, confirming PhtD as a factor-H binding protein. Our results support the inclusion of PhtD and more specifically, its C-terminal fragment in a multicomponent serotype independent vaccine and suggests a role for the complement system in PhtD-mediated protection. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Protective role of PhtD and its amino and carboxyl fragments against pneumococcal sepsis
- Author
-
Abiodun D. Ogunniyi, Lucas Assoni, David L. Gordon, Lúcio Fábio Caldas Ferraz, Henrietta Venter, Piplani Sakshi, Greiciely O. Andre, Michelle Darrieux, Mayara T. Borges, Thiago Rojas Converso, Penelope J. Adamson, André, Greiciely O, Borges, Mayara T, Assoni, Lucas, Ferraz, Lucio FC, Sakshi, Piplani, Adamson, Penelope, Gordon, David L, Ogunniyi, Abiodun D, Venter, Henrietta, Converso, Thiago R, and Darrieux, Michelle
- Subjects
pneumococcal vaccine ,030231 tropical medicine ,PhtD ,Bacteremia ,Biology ,medicine.disease_cause ,Pneumococcal Infections ,Microbiology ,Pneumococcal Vaccines ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Bacterial Proteins ,Antigen ,Streptococcus pneumoniae ,medicine ,Animals ,030212 general & internal medicine ,complement system ,streptococcus pneumoniae ,General Veterinary ,General Immunology and Microbiology ,Public Health, Environmental and Occupational Health ,factor H ,Antibodies, Bacterial ,Complement system ,Infectious Diseases ,Pneumococcal vaccine ,Immunization ,invasive disease ,Alternative complement pathway ,biology.protein ,Molecular Medicine ,Antibody - Abstract
The implementation of polysaccharide-based vaccines has massively reduced the incidence of invasive pneumococcal diseases. However, there is great concern regarding serotype replacement and the increase in antibiotic resistant strains expressing non-vaccine capsular types. In addition, conjugate vaccines have high production costs, a limiting factor for their implementation in mass immunization programs in developing countries. These limitations have prompted the development of novel vaccine strategies for prevention of Streptococcus pneumoniae infections. The use of conserved pneumococcal antigens such as recombinant proteins or protein fragments presents an interesting serotype-independent alternative. Pht is a family of surface-exposed proteins which have been evaluated as potential vaccine candidates with encouraging results. The present work investigated the immune responses elicited by subcutaneous immunization of mice with the polyhistidine triad protein D (PhtD) and its amino and carboxyl terminal fragments. The proteins were immunogenic and protective against pneumococcal sepsis in mice. Antibodies raised against PhtD increased complement C3b deposition on the pneumococcal surface,mainly mediated by the alternative pathway. Sera from mice immunized with PhtD and PhtD_Cter promoted an increase in bacterial uptake by mouse phagocytes. The interaction of PhtD with the complement system regulator factor H was investigated in silico and in vitro by ELISA and western blot,confirming PhtD as a factor-H binding protein. Our results support the inclusion of PhtD and more specifically, its C-terminal fragment in a multicomponent serotype independent vaccine and suggests a role for the complement system in PhtD-mediated protection. Refereed/Peer-reviewed
- Published
- 2021
31. Recent advances in the therapeutic potential of cathelicidins.
- Author
-
Guerra MES, Vieira B, Calazans APCT, Destro GV, Melo K, Rodrigues E, Waz NT, Girardello R, Darrieux M, and Converso TR
- Abstract
The alarming increase in antimicrobial resistance in the last decades has prompted the search for alternatives to control infectious diseases. Antimicrobial peptides (AMPs) represent a heterogeneous class of molecules with ample antibacterial, antiviral, and antifungal effects. They can be found in many organisms, including all classes of vertebrates, providing a valuable source of new antimicrobial agents. The unique properties of AMPs make it harder for microbes develop resistance, while their immunomodulatory properties and target diversity reinforce their translational use in multiple diseases, from autoimmune disorders to different types of cancer. The latest years have witnessed a vast number of studies evaluating the use of AMPs in therapy, with many progressing to clinical trials. The present review explores the recent developments in the medicinal properties of cathelicidins, a vast family of AMPs with potent antimicrobial and immunomodulatory effects. Cathelicidins from several organisms have been tested in disease models of viral and bacterial infections, inflammatory diseases, and tumors, with encouraging results. Combining nanomaterials with active, natural antimicrobial peptides, including LL-37 and synthetic analogs like ceragenins, leads to the creation of innovative nanoagents with significant clinical promise. However, there are still important limitations, such as the toxicity of many cathelicidins to healthy host cells and low stability in vivo . The recent advances in nanomaterials and synthetic biology may help overcome the current limitations, enabling the use of cathelicidins in future therapeutics. Furthermore, a better understanding of the mechanisms of cathelicidin action in vivo and their synergy with other host molecules will contribute to the development of safer, highly effective therapies., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Guerra, Vieira, Calazans, Destro, Melo, Rodrigues, Waz, Girardello, Darrieux and Converso.)
- Published
- 2024
- Full Text
- View/download PDF
32. Functional Insights From KpfR, a New Transcriptional Regulator of Fimbrial Expression That Is Crucial for Klebsiella pneumoniae Pathogenicity.
- Author
-
Gomes AÉI, Pacheco T, Dos Santos CDS, Pereira JA, Ribeiro ML, Darrieux M, and Ferraz LFC
- Abstract
Although originally known as an opportunistic pathogen, Klebsiella pneumoniae has been considered a worldwide health threat nowadays due to the emergence of hypervirulent and antibiotic-resistant strains capable of causing severe infections not only on immunocompromised patients but also on healthy individuals. Fimbriae is an essential virulence factor for K. pneumoniae , especially in urinary tract infections (UTIs), because it allows the pathogen to adhere and invade urothelial cells and to form biofilms on biotic and abiotic surfaces. The importance of fimbriae for K. pneumoniae pathogenicity is highlighted by the large number of fimbrial gene clusters on the bacterium genome, which requires a coordinated and finely adjusted system to control the synthesis of these structures. In this work, we describe KpfR as a new transcriptional repressor of fimbrial expression in K. pneumoniae and discuss its role in the bacterium pathogenicity. K. pneumoniae with disrupted kpfR gene exhibited a hyperfimbriated phenotype with enhanced biofilm formation and greater adhesion to and replication within epithelial host cells. Nonetheless, the mutant strain was attenuated for colonization of the bladder in a murine model of urinary tract infection. These results indicate that KpfR is an important transcriptional repressor that, by negatively controlling the expression of fimbriae, prevents K. pneumoniae from having a hyperfimbriated phenotype and from being recognized and eliminated by the host immune system., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Gomes, Pacheco, Santos, Pereira, Ribeiro, Darrieux and Ferraz.)
- Published
- 2021
- Full Text
- View/download PDF
33. Immunization with PhtD truncated fragments reduces nasopharyngeal colonization by Streptococcus pneumoniae.
- Author
-
André GO, Assoni L, Rodriguez D, Leite LCC, Dos Santos TEP, Ferraz LFC, Converso TR, and Darrieux M
- Subjects
- Animals, Antibodies, Bacterial, Bacterial Proteins genetics, Immunization, Mice, Pneumococcal Infections prevention & control, Pneumococcal Vaccines, Streptococcus pneumoniae immunology
- Abstract
Despite the undeniable success of polysaccharide vaccines against Streptococcus pneumoniae infections, there is a consensus on the scientific field that this approach should be revised in order to overpass the problems related with these formulations, such as serotype replacement and high production costs. The study of conserved pneumococcal proteins or its truncated fragments has emerged as a serotype independent alternative. In this work, we have characterized the immune response elicited by systemic immunization of mice with the Histidine triad protein D (PhtD) and its' amino and carboxyl terminal fragments. The proteins were shown to be immunogenic and protective against pneumococcal colonization, with increased IL-17 production, and induction of antibodies able to limit pneumococcal adhesion to human respiratory cells. Antiserum against PhtD_Nter, but not C_ter or PhtD, promoted an increase in bacterial phagocytosis in vitro. Interestingly, antibodies against the PhtD_Nter displayed cross-reactivity with two other pneumococcal proteins, PspA and PspC, due to sequence similarities in the proline rich region of the molecules. On a whole, our results support the inclusion of PhtD, and more specifically, its N-terminal fragment, in a multicomponent serotype independent vaccine., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
34. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.
- Author
-
Moreno AT, Oliveira ML, Ferreira DM, Ho PL, Darrieux M, Leite LC, Ferreira JM Jr, Pimenta FC, Andrade AL, and Miyaji EN
- Subjects
- Animals, Bacterial Proteins chemistry, Cross Reactions immunology, Enzyme-Linked Immunosorbent Assay, Female, Heat-Shock Proteins chemistry, Mice, Mice, Inbred BALB C, Streptococcus pneumoniae, Vaccination, Antibodies, Bacterial immunology, Bacterial Proteins immunology, Complement System Proteins immunology, Cross Protection immunology, Heat-Shock Proteins immunology, Pneumococcal Infections prevention & control, Pneumococcal Vaccines immunology
- Abstract
PspA is an important candidate for a vaccine with serotype-independent immunity against pneumococcal infections. Based on sequence relatedness, PspA has been classified into three families comprising six clades. We have previously addressed the cross-reactivity of antibodies against PspA fragments containing the N-terminal and proline-rich regions of PspA from clades 1 to 5 (PspA1, PspA2, PspA3, PspA4, and PspA5) by Western blot analysis and reported that anti-PspA4 and anti-PspA5 were able to recognize pneumococci expressing PspA proteins from all of the clades analyzed. We have now analyzed the functional capacity of these antibodies to bind and to mediate complement deposition on intact bacteria in vitro. Our results show that both PspA4 and PspA5 elicit antibodies that are able to bind and to mediate complement deposition efficiently on pneumococcal strains bearing PspA proteins from clades 1 to 5. Moreover, mice immunized with PspA4 and PspA5 were protected against an intranasal lethal challenge with strains expressing PspA proteins from the two major families. PspA4 and PspA5 are thus able to induce antibodies with a high degree of cross-reactivity in vitro, which is reflected in cross-protection of mice. We have also analyzed the contribution of the nonproline (NonPro) block within the conserved proline-rich region to the reactivity of anti-PspA antibodies, and the results indicate that N-terminal alpha-helical region, the blocks of proline repeats, and the NonPro region can influence the degree of cross-reactivity of antibodies to PspA.
- Published
- 2010
- Full Text
- View/download PDF
35. Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production.
- Author
-
Ferreira DM, Darrieux M, Oliveira ML, Leite LC, and Miyaji EN
- Subjects
- Animals, Antibodies, Bacterial blood, Bacterial Proteins genetics, Bacterial Proteins metabolism, Female, Humans, Interferon-gamma biosynthesis, Interleukin-4 genetics, Mice, Mice, Inbred BALB C, Mice, Knockout, Pneumococcal Infections immunology, Pneumococcal Infections microbiology, Pneumococcal Infections physiopathology, Pneumococcal Infections prevention & control, Pneumococcal Vaccines administration & dosage, Pneumococcal Vaccines genetics, Streptococcus pneumoniae immunology, Streptococcus pneumoniae pathogenicity, Tumor Necrosis Factor-alpha biosynthesis, Vaccines, DNA administration & dosage, Vaccines, DNA genetics, Bacterial Proteins immunology, Cytokines biosynthesis, Immunoglobulin G blood, Inflammation immunology, Pneumococcal Vaccines immunology, Vaccines, DNA immunology
- Abstract
We have previously shown that DNA immunization with PspA (pneumococcal surface protein A) DNA is able to elicit protection comparable to that elicited by immunization with PspA protein (with alum as adjuvant), even though the antibody levels elicited by DNA immunization are lower than those elicited by immunization with the protein. This work aims at characterizing the ability of sera to bind to the pneumococcal surface and to mediate complement deposition, using BALB/c wild-type and interleukin-4 knockout mice. We observed that higher anti-PspA levels correlated with intense antibody binding to the pneumococcal surface, while elevated complement deposition was observed with sera that presented balanced immunoglobulin G1 (IgG1)/IgG2a ratios, such as those from DNA-immunized mice. Furthermore, we demonstrated that gamma interferon and tumor necrosis factor alpha were strongly induced after intraperitoneal pneumococcal challenge only in mice immunized with the DNA vaccine. We therefore postulate that although both DNA and recombinant protein immunizations are able to protect mice against intraperitoneal pneumococcal challenge, an optimized response would be achieved by using a DNA vaccine and other strategies capable of inducing balanced Th1/Th2 responses.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.